Protalix BioTherapeutics Competitors and Similar CompaniesClear all
Protalix BioTherapeutics's competitors and similar companies include iBio, Pharming Group, UCB and Genentech.
 Protalix BioTherapeutics Protalix is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins. |  Pharming Group Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. |  Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines. | ||
Founding Date | Founding Date 1994 | Founding Date 2008 | Founding Date 1988 | Founding Date 1928 | Founding Date 1976 |
Type | Type Public | Type Public | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Karmiel, IL HQ | Locations San Diego, US HQ Bryan, US | Locations Leiden, NL HQ Leiden, NL | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more |
Employees | Employees 213 | Employees 1630% decrease | Employees 404 | Employees 9,052 | Employees 18,077 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 26.2 m | Valuation ($) 590.3 m | Valuation ($) 34.3 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $52.7m (FY, 2025) | Revenue (est.) $400k (FY, 2025) | Revenue (est.) $376.1m (FY, 2025) | Revenue (est.) €7.4b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $25.5m (FY, 2025) | Cost of goods N/A | Cost of goods $41.6m (FY, 2025) | Cost of goods €1.4b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $27.2m (FY, 2025) | Gross profit N/A | Gross profit $341m (FY, 2025) | Gross profit €7.2b (FY, 2025) | Gross profit N/A |
Net income | Net income ($6.6m) (FY, 2025) | Net income N/A | Net income $2.5m (FY, 2025) | Net income €1.6b (FY, 2025) | Net income N/A |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (Q3, 2020) | Phase I Trials Products N/A | Phase I Trials Products 28 (Jul, 2025) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 1 (Q3, 2020) | Phase II Trials Products N/A | Phase II Trials Products 19 (Jul, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 62.5m | Total funding raised $ 9.3m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Pharming Group
HQ
Leiden, NL
Employees
404
Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases.
View companyUCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View companyGenentech
HQ
South San Francisco, US
Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.
View company